LUCD stock news · Lucid Diagnostics
Get alerts for LUCD
Follow Lucid Diagnostics (LUCD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LUCD12 health care companies are seeing big changes in their stock prices today.
NeutralLucid Diagnostics’ share price rose about 34% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
12 health care companies are changing a lot in Friday's early trading.
NeutralLucid Diagnostics' shares rose about 30% in Friday's pre-market session, but the article reports no company news. The move alone does not change Lucid's business outlook.
Lucid Diagnostics Inc. has been told it might be removed from Nasdaq for not meeting listing rules.
Bad for LUCDLucid received a Nasdaq warning after its closing bid stayed below $1 for 30 business days. The risk to its listing makes this negative news for the company.
12 health care stocks changed a lot in prices after the market closed on Thursday.
NeutralLucid Diagnostics shares fell about 6% to $0.60 after hours, but the article reports no business update or reason for the move. It does not change the company's outlook.
On Thursday, 12 health care stocks saw big price changes, with Nexalin Technology jumping up 77.8%.
NeutralLucid Diagnostics shares fell 20.04% during Thursday's session, but the article gives no company news explaining the drop, so its business outlook is unchanged.
Analyst suggests Lucid Diagnostics may be prioritized for a Medicare coverage ruling.
Good for LUCDLucid Diagnostics is positioned favorably for Medicare coverage of its EsoGuard test, which could lead to increased revenue and market access. The company's recent contract win with Concert and positive analyst outlook suggest a strong potential for growth, making it a stock to watch in the coming months.
Full transcript of Lucid Diagnostics' earnings call for Q2 2026 released.
Good for LUCDLucid Diagnostics' Q2 2026 earnings call revealed a 17% increase in revenue, driven by a rise in EsoGuard tests and the acquisition of a significant commercial coverage policy. This development is expected to enhance the company's market presence and could lead to increased coverage from other laboratory benefit managers, positively impacting its addressable market.
Lucid Diagnostics Inc. provides updates on operational performance and financial status (LUCD).
NeutralLucid Diagnostics Inc. has filed a Form 8-K that includes important updates on its operations and financial condition. This filing is essential for stakeholders to assess the company's current performance and future outlook, potentially impacting trading decisions.